CEDAR KNOLLS, NJ--(Marketwired - Oct 29, 2013) - MYOS Corporation (OTCBB: MYOS), a company focused on the discovery, development and commercialization of products that improve human muscle health and performance ("MYOS"), today announced that it has been selected to present research at the 7th International Conference of the Society on Sarcopenia, Cachexia, and Wasting Disorders to be held December 9th - 11th, 2013 in Kobe Japan. MYOS' presentation will highlight the characterization of the fertilized chicken egg proteome and lipidome by high resolution mass spectrometry. Fertilized chicken egg yolk is an essential source of active proteins in MYOS' first commercial product, MYO-X, a unique orally administered dietary supplement clinically shown to reduce serum myostatin levels. Reducing myostatin is believed to have benefits in improving the health and performance of muscle tissue. MYOS is working to further characterize other beneficial proteins, lipids and other bioactive molecules found in MYO-X.
Sarcopenia is the degenerative loss of skeletal muscle mass (0.5 to 1% loss per year after the age of 25), quality and strength associated with aging and is a component of frailty syndrome. Cachexia is the wasting syndrome characterized by loss of weight, muscle atrophy weakness and fatigue which accompanies a range of chronic illnesses including cancer, HIV-AIDS, COPD, degenerative neurologic disorders such as multiple sclerosis, congestive heart disease, tuberculosis and renal disease. These conditions represent two principle targets for therapeutic and nutritional products which improve muscle health.
Commenting on these MYOS research activities, Louis Aronne, M.D., a member of MYOS Board of Directors said, "MYOS' ongoing research suggests potentially unique therapeutic implications for the treatment of sarcopenia and cachexia. Our proteomic research has identified proteins relevant to the formation of muscle tissue as well as those with possible anti-inflammatory properties."
The presentation will highlight research relating to the characterization of proteins and lipids that are naturally present in MYO-X, powered by MYO-T12, the world's first clinically proven natural myostatin inhibitor. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. The research presented will provide new insights into the possible mechanisms through which MYO-X exerts its beneficial effects on muscle. Further information on the conference can be found at ww.cachexia.org. of sarcopenia, cachexia, and other muscle wasting diseases. MYOS expects to publish this research in the December issue of the Journal of Cachexia, Sarcopenia and Muscle (www.jcsm.info).
MYOS Chairman Robert Hariri, M.D., PhD added, "As an emerging bio therapeutics company focused on muscle health, the ability to understand both the protein and lipid characteristics of our products is essential to fully exploiting the therapeutic potential of MYO-T12 and other future MYOS products. MYOS is committed to developing therapeutic and nutritional products which improve muscle health and performance."
About MYOS Corporation
MYOS is a developmental stage company focused on the discovery, development and commercialization of products that improve human muscle health and performance. MYOS owns MYO-T12, the world's first clinically proven natural myostatin inhibitor. Medical literature suggests that lowering myostatin levels has many potential health benefits including increased muscle mass, healthy weight management, improved energy levels, stimulation of muscle healing as well as treating sarcopenia, a condition of age-related loss of muscle mass. For more information on MYO-T12 and to discover why MYOS is known as "The Muscle Company,"™ visit www.myoscorp.com.
The Company's first commercial product MYO-X™, powered by MYO-T12, is distributed by Maximum Human Performance (MHP) and is currently available on popular e-tailer websites including www.mhpstrong.com and www.bodybuilding.com and in specialty retailers including GNC and Vitamin Shoppe. MYOS believes that MYO-X, as well as future products it envisions, will redefine existing standards for muscle health.
Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to the successful continued research of MYO-T12 and its effects on myostatin inhibition, including the study described herein, product and customer demand, the continued growth of repeat purchases, market acceptance of our products, the ability to create new products through research and development, the continued growth in revenue, the ability to generate the forecasted revenue stream and cash flow from sales of MYO-X, the ability to achieve a sustainable profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, the continued growth and expansion of MYO-X in GNC, Vitamin Shoppe and other specialty retail stores, the ability to strengthen our manufacturing relationships and reduce the costs of our products, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in our Securities and Exchange Commission filings. We undertake no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.